Autolus Therapeutics
Update in progressAUTL (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Autolus Therapeutics plc is a London-based clinical-stage biopharmaceutical company developing T cell therapies for cancer and autoimmune diseases worldwide. Its lead product AUCATZYL uses autologous T cells engineered with a lentiviral anti‑CD19 CAR. It also advances obe-cel (phase 1–2) for lupus, multiple sclerosis, B‑NHL, CLL, CNS lymphoma, pediatric B‑ALL and lupus nephritis; AUTO1/22; AUTO8; and several earlier programs, founded in 2014.
Company score
- Sentiment
- 0.49
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.55
- Governance
- 0.22
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.22
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.35
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited Kingdom
- CEODr. Christian Martin Itin Ph.D.
- Founded2014
- Employees752
- Websitewww.autolus.com
Identifiers
- ISINUS05280R1005
- FIGIBBG00KVT05R6
- LEI549300C0KZP8EYROLL02
- CUSIP05280R100
- CIK0001730463